A prospective, double-blind, multi center, randomized clinical study to compare the efficacy and safety of ertapenem 3 days versus ampicillin-sulbactam [sulbactam/ampicillin] 3 days in the treatment of localized community acquired intra-abdominal infection (IAI). (T.E.A. study three days ertapenem vs three days ampicillin- sulbactam).

Trial Profile

A prospective, double-blind, multi center, randomized clinical study to compare the efficacy and safety of ertapenem 3 days versus ampicillin-sulbactam [sulbactam/ampicillin] 3 days in the treatment of localized community acquired intra-abdominal infection (IAI). (T.E.A. study three days ertapenem vs three days ampicillin- sulbactam).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Ertapenem (Primary) ; Sulbactam/ampicillin
  • Indications Bacterial infections; Intra-abdominal infections
  • Focus Therapeutic Use
  • Acronyms TEA
  • Most Recent Events

    • 17 Aug 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 17 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top